EU Approves Pharming's Joenja as First Treatment for Rare APDS Disease
summarizeSummary
The European Commission has granted marketing authorization for Pharming's Joenja® (leniolisib) for Activated PI3K delta Syndrome (APDS) in the EU. This makes Joenja the first and only approved treatment for APDS in the European Union. This definitive approval follows the positive CHMP opinion issued on March 27, 2026, and significantly expands the market for this key product. The first European launch is anticipated in Germany in Q3 2026, with further launches pending reimbursement negotiations.
At the time of this announcement, PHAR was trading at $12.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $918M. The 52-week trading range was $8.69 to $21.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.